Search Protocols under revision. Back New search Go to resultsDiseaseMain groupCross-Sectional, Transplantation, Cellular TherapyPediatric Oncology and HematologyProtocol groupLeukemias (ped.)RadiotherapyDiseaseAcute Lymphoblastic LeukaemiaMalignant MeningitisSubgroupB-ALLLeukemic MeningitisT-ALLICD10C79.3C91.0-MeSHMeningeal CarcinomatosisPrecursor B-Cell Lymphoblastic Leukemia-LymphomaPrecursor T-Cell Lymphoblastic Leukemia-LymphomaSequenceAIEOP-BFM ALL 2024 B-ALLAIEOP-BFM ALL 2024 T-ALLChemotherapyChemo-substanceAmsacrineBlinatumomabClofarabinCyclophosphamideCytarabineDaunorubicinDexamethasoneDoxorubicinDoxorubicin liposomalEtoposideEtoposide phosphateFludarabineIfosfamideMercaptopurineMethotrexateMethylprednisolonePeg asparaginasePrednisoloneTioguaninVincristineVindesineChemo-substanceAmsacrineBlinatumomabClofarabinCyclophosphamideCytarabineDaunorubicinDexamethasoneDoxorubicinDoxorubicin liposomalEtoposideEtoposide phosphateFludarabineIfosfamideMercaptopurineMethotrexateMethylprednisolonePeg asparaginasePrednisoloneTioguaninVincristineVindesineChemo-substanceAmsacrineBlinatumomabClofarabinCyclophosphamideCytarabineDaunorubicinDexamethasoneDoxorubicinDoxorubicin liposomalEtoposideEtoposide phosphateFludarabineIfosfamideMercaptopurineMethotrexateMethylprednisolonePeg asparaginasePrednisoloneTioguaninVincristineVindesineChemo-substanceAmsacrineBlinatumomabClofarabinCyclophosphamideCytarabineDaunorubicinDexamethasoneDoxorubicinDoxorubicin liposomalEtoposideEtoposide phosphateFludarabineIfosfamideMercaptopurineMethotrexateMethylprednisolonePeg asparaginasePrednisoloneTioguaninVincristineVindesineNo. Substances12345678910 RadiotherapySupportive therapySupportive substanceAllopurinolAmphotericin BBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneDextrose 5%FilgrastimFluorometholoneFolinic acidFosaprepitantGranisetronHyaluronic acidLevetiracetamMesnaMethylprednisoloneNaCl 0.9%NaCl 0.45%ParacetamolPotassium chloridePyridoxineSodium BicarbonateSupportive substanceAllopurinolAmphotericin BBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneDextrose 5%FilgrastimFluorometholoneFolinic acidFosaprepitantGranisetronHyaluronic acidLevetiracetamMesnaMethylprednisoloneNaCl 0.9%NaCl 0.45%ParacetamolPotassium chloridePyridoxineSodium BicarbonateSupportive substanceAllopurinolAmphotericin BBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneDextrose 5%FilgrastimFluorometholoneFolinic acidFosaprepitantGranisetronHyaluronic acidLevetiracetamMesnaMethylprednisoloneNaCl 0.9%NaCl 0.45%ParacetamolPotassium chloridePyridoxineSodium BicarbonateSupportive substanceAllopurinolAmphotericin BBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneDextrose 5%FilgrastimFluorometholoneFolinic acidFosaprepitantGranisetronHyaluronic acidLevetiracetamMesnaMethylprednisoloneNaCl 0.9%NaCl 0.45%ParacetamolPotassium chloridePyridoxineSodium BicarbonateNo. Substances12345789101113Protocol classificationTherapy classificationcurrent standardstudy analogStudy protocol, currentIntensityhigh doseStandard doseTherapy indicationFirst lineTherapy phaseConsolidationInductionMaintenancePre-phaseReinductionTherapy intentioncurativeRisksEmetogenicityEmetogenicity (MASCC/ESMO)Febrile NeutropeniaNeutropenia only studiesPublicationAuthorAIEOPAIOEPHorstmann MDiseaseNeudiagnostizierte B-/T-ALL, BCR:ABL-, Erstlinie, Alter 1-18 JahreNeudiagnostizierte B-ALL, BCR:ABL-, Erstlinie, Alter 1-18 JahreNeudiagnostizierte T-ALL, BCR:ABL-, Erstlinie, Alter 1-18 JahreVorläufer-B- und T-Zell Leukämie, Hochrisiko ALLOriginAIEOP-BFM ALL 2024 Gesellschaft für Pädiatrische Onkologie und Hämatologie, Studienprotokoll COALL 08-09Protocols in Revision 48 protocols foundAIEOP-BFM ALL 2024, BLIN, B-lymphoblastic leukemia (PID3020 V1.0)AIEOP-BFM ALL 2024, Cons A extended, B-lymphoblastic leukemia (PID1013 V1.0)AIEOP-BFM ALL 2024, Cons A short, B-lymphoblastic leukemia (PID3006 V1.0)AIEOP-BFM ALL 2024, Cons B extended, B-lymphoblastic leukemia (PID1016 V1.0)AIEOP-BFM ALL 2024, Cons B short, B-lymphoblastic leukemia (PID3007 V1.0)AIEOP-BFM ALL 2024, maintenance, B-lymphoblastic leukemia, high risk / intermediate risk CNS2c/3, part B (PID3033 V1.0)AIEOP-BFM ALL 2024, maintenance, B-lymphoblastic leukemia, high-risk, part A (PID3030 V1.0)AIEOP-BFM ALL 2024, maintenance, B-lymphoblastic leukemia, intermediate risk CNS2c/3, part A (PID3031 V1.0)AIEOP-BFM ALL 2024, maintenance, B-lymphoblastic leukemia, standard / intermediate risk (PID3032 V1.0)AIEOP-BFM ALL 2024, maintenance, T-lymphoblastic leukemia, interim (PID3021 V1.0)AIEOP-BFM ALL 2024, maintenance, T-lymphoblastic leukemia, part A (PID3022 V1.0)AIEOP-BFM ALL 2024, maintenance, T-lymphoblastic leukemia, part B (PID3029 V1.0)AIEOP-BFM ALL 2024, HR-1', B-lymphoblastic leukemia (PID1021 V1.0)AIEOP-BFM ALL 2024, HR-2', B-lymphoblastic leukemia (PID1022 V1.0)AIEOP-BFM ALL 2024, HR-3', B-lymphoblastic leukemia (PID1023 V1.0)AIEOP-BFM ALL 2024, IA'-Pred, B-lymphoblastic leukemia (PID1017 V1.0)AIEOP-BFM ALL 2024, IA-CPM, T-acute Lymphoblastic Leukaemia (PID1010 V1.0)AIEOP-BFM ALL 2024, IA-DXM, T- Acute Lymphoblastic Leukaemia (PID1008 V1.1)AIEOP-BFM ALL 2024, IA-Pred, B-Acute Lymphoblastic Leukaemia (PID1009 V1.0)AIEOP-BFM ALL 2024, IB, T-lymphoblastic leukemia (PID1011 V1.0)AIEOP-BFM ALL 2024, IIA, B-lymphoblastic leukemia (PID1012 V1.0)AIEOP-BFM ALL 2024, IIB, B-lymphoblastic leukemia (PID1015 V1.0)AIEOP-BFM ALL 2024, IIIA, B-lymphoblastic leukemia (PID1018 V1.0)AIEOP-BFM ALL 2024, IIIB, B-lymphoblastic leukemia (PID1019 V1.0)AIEOP-BFM ALL 2024, M, B-lymphoblastic leukemia (PID1014 V1.0)AIEOP-BFM ALL 2024, Myo-FLA, B-lymphoblastic leukemia (PID1025 V1.0)PAED COALL 08-09, maintenance, B-ALL/T-ALL, LR-reduced, and HR-reduced (PID24 V1.0)PAED COALL 08-09, Maintenance, B-ALL/T-ALL, LR-Standard and LR-Intensified and HR-Standard and HR- Intensified (PID25 V1.0)PAED COALL 08-09, maintenance, B-ALL/T-ALL, MTX intrathecal (without CNS irradiation) (PID33 V1.0)PAED COALL 08-09, induction, all patients (PID11 V1.0)PAED COALL 08-09, Intensive phase, B-ALL, HR-Intensified C1a-C4-C4-C3-C3-C1a-C5 (PID19 V1.0)PAED COALL 08-09, intensive phase, B-ALL, HR-Intensified C1b-C4-C3-C3-C1a-C5 (PID20 V1.0)PAED COALL 08-09, intensive phase, B-ALL, LR intensified and HR reduced, and HR standard C1a-C4-C4-C3-C3-C1a (PID15 V1.0)PAED COALL 08-09, intensive phase, B-ALL, LR intensified and HR standard C1b-C4-C4-C3-C3-C1a (PID14 V1.0)PAED COALL 08-09, intensive phase, B-ALL, LR standard C1b-C2-C3-C2 (PID13 V1.0)PAED COALL 08-09, Intensive Phase, B-ALL, LR Standard and LR Reduced C1a-C2-C3-C2. (PID12 V1.0)PAED COALL 08-09, intensive phase, T-ALL, HR-Intensified C4-C1a-C4-C3-C3-C1a-C5 (PID18 V1.0)PAED COALL 08-09, intensive phase, T-ALL, HR standard C4-C1b-C4-C3-C1a (PID17 V1.0)PAED COALL 08-09, intensive phase, T-ALL, HR standard and HR reduced C4-C1a-C4-C3-C3-C1a (PID16 V1.0)PAED COALL 08-09, Reinduction, B-ALL, LR-Standard R2(ADR)-R3 (PID30 V1.0)PAED COALL 08-09, Reinduction, B-ALL, LR-Standard R2(DNR)-R3 (PID22 V1.0)PAED COALL 08-09, Reinduction, B-ALL/T-ALL, HR Intensified R2 before CNS (PID32 V1.0)PAED COALL 08-09, Reinduction, B-ALL/T-ALL, LR-Intensified and HR-Standard and HR-Intensified R2(ADR)-R2-R3-R3 (PID31 V1.0)PAED COALL 08-09, Reinduction, B-ALL/T-ALL, LR-Intensified and HR-Standard and HR-Intensified R2(DNR)-R2-R3-R3 (PID23 V1.0)PAED COALL 08-09, Reinduction, B-ALL/T-ALL, LR-Reduced and HR-Reduced R1 (PID21 V1.0)PAED COALL 08-09, Pre-phase, all patients (PID10 V1.0)PAED COALL 08-09, CNS, B-ALL/T-ALL, initial CNS involvement (PID29 V1.0)PAED COALL 08-09, CNS, B-ALL/T-ALL, LR and HR (B-ALL leukoc. up to 200000/µl, T-ALL leukoc. up to 100000/µl) (PID28 V1.0)
